Stay updated with breaking news from Initial Findings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed... | June 7, 2023
Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safety and... | April 18, 2023
A new science-based factual show is nearing completion at QTQ9's very busy Kid's Unit.
Another four working sessions will be scheduled in April.
Editor’s Note: America spends more on health care per person than any other developed country, only to have the lowest life expectancy among them. Despite our expenditures—now one out...